Norway· NO-ID_F5C154A3-FC3D-436C-8EC3-3B384BE5B16F
Proleukin S
A aldesleukin product containing aldesleukin, registered in Norway by Clinigen. The same ATC class is registered in 10 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Aldesleukin is registered in 10 of 19 countries.
Countries holding a registration under ATC L03AC01 (aldesleukin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 6 of them publish a price we can compare per daily dose
Aldesleukin · ATC L03AC01
10 / 19 countries
- Belgiumprice
- Canada
- Finlandprice
- Franceprice
- Germany
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Aldesleukin
- Manufacturer
- Clinigen
- Country
- Norway (NO)
- ATC code
- L03AC01
- ATC class
- Aldesleukin
- Defined daily dose
- 0.2 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- October 2, 2026
Packs & prices · 3
- no_merkevare_idID_F5C154A3-FC3D-436C-8EC3-3B384BE5B16F
- no_varenummer34455922
- gtin4150167718112
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
472 interactions on record for aldesleukin.
Graded by severity as the source publishes them — 46 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aldesleukin · interactions on record
472 records
- 46 severe
- 411 moderate
- 15 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CidofovirJ05AB12severe
- DacarbazineL01AX04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aldesleukin in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesGUNA-IL 2Guna spa
- GermanyProleukin SIovance Biotherapeutics B.V
- FinlandProleukinNovartis Finland Oy
- FrancePROLEUKIN 18 millions U.I., poudre pour solution injectableIOVANCE BIOTHERAPEUTICS (PAYS-BAS)
- SpainPROLEUKIN 18 X 10(6) UI POLVO PARA SOLUCION INYECTABLE O PARA PERFUSIONIovance Biotherapeutics B.V.
- NetherlandsProleukin 18 x 1.000.000 IE poeder voor oplossing voor injectie of infusieIovance Biotherapeutics B.V.
- BelgiumProleukin 18 10*6 IUNovartis Pharma
- CanadaPROLEUKINSTERIMAX INC
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Austria · Proleukin
- Germany · Proleukin S
- Spain · Proleukin
- France · Proleukin
- United Kingdom (Northern Ireland) · Proleukin
- Italy · Proleukin
- Netherlands · Proleukin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6171fc5a-73b2-4f9b-b9d1-704020e94561 GET /v1/drugs/6171fc5a-73b2-4f9b-b9d1-704020e94561?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til injeksjons-/infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Aldesleukin",
"merkevare_id": "ID_F5C154A3-FC3D-436C-8EC3-3B384BE5B16F",
"name_form_strength": "Proleukin S pulv til inj/inf væske, oppl 18 mill IE/ml",
"prescription_group": "C"
}See everything about aldesleukin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.